Neumora Therapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Neumora Therapeutics stock has a consensus rating of "Buy" and an average price target of $6.53. The average 1-year stock price forecast is 279.65% higher than the current stock price, while the lowest is $3.00 (+74.42%) and the highest is $14 (+713.95%).

Price Target: $6.53 (+279.65%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$3.00	$6.53	$6.00	$14
Change	+74.42%	+279.65%	+248.84%	+713.95%

Analyst Ratings

The average analyst rating for Neumora Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	5	5	5	5	5
Buy	2	2	2	2	2	2
Hold	2	1	1	1	1	1
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	9	9	9	9	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Graig Suvannavejh Mizuho Securities	Mizuho Securities	Buy Maintains $4	Buy	Maintains	$4	+132.56%	Jun 22, 2026
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Buy Reiterates $18 → $7	Buy	Reiterates	$18 → $7	+306.98%	Jun 16, 2026
Ami Fadia Needham	Needham	Buy Reiterates $8 → $5	Buy	Reiterates	$8 → $5	+190.70%	Jun 15, 2026
Myles Minter William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jun 15, 2026
Tessa Romero J.P. Morgan	J.P. Morgan	Sell Maintains n/a	Sell	Maintains	n/a	n/a	May 27, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

3.56M

EPS This Year

-0.92

from -1.45

EPS Next Year

-0.77

from -0.92

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-80.32M	-122.87M	-188.19M	-263.46M	-236.16M	-175.27M
Net Income	-237.31M	-130.90M	-235.93M	-243.79M	-236.93M	-176.95M
EPS	-	-	-	-	-1.45	-0.92
Free Cash Flow	-37.08M	-93.02M	-111.24M	-100.70M	-115.71M	-147.47M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-0.67
Avg	-0.92
Low	-1.29

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-